Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

JPND Presentation P. Amouyel

1,750 views

Published on

A JPND presentation by Philippe Amouyel, Chair of JPND Management Board

  • Be the first to comment

  • Be the first to like this

JPND Presentation P. Amouyel

  1. 1. Joint Programming Initiative onNeurodegenerative Diseases Prof. Philippe Amouyel Chair, JPND Management Board
  2. 2. Frequence of Neurodegenerative Diseases 40 30 Dementia Cases / 100 20 Stroke 10 Parkinsons 0 60 70 80 90 100 Age (years)From Rocca W et al, Eurodem
  3. 3. PopulationProjections and Ageing 30 More developed regions 30 Less developed regions % of total population 60 + 20 20 60 + 10 70 + 10 70 + 80 + 80 + 0 0 1950 1970 1990 2010 2030 1950 1970 1990 2010 2030 Calendar year Calendar year
  4. 4. Alzheimer’s disease in Europe Number of cases Societal costs (€) 2010 6,000,000 72,000,000,000 2040 12,000,000 144,000,000,000
  5. 5. Research challenges• 30% of healthy elderly subjects already have Alzheimer pathology Cognitively normal subject aged 72 years with Alzheimer pathology (red)
  6. 6. A major societal challenge for the coming years
  7. 7. Research efforts are fragmented Ocean energy Investing more than the US Concentrated solar thermal Nuclear fusion Pollution and environmental protection CO2 capture and storage nanotechnology’s Photovoltaic potential risks Hydrogen and Biomass - Bioenergy Agriculture Production fuel cells Wind energy much as the US and Technology Investing as Polar programs Nanotechnologies Geothermal Grids electricity Cancer Space Information and communication technology Civil security Investing less than the US Biotechnologies Brain diseases Industrial biotechnology Low coordination/ High fragmentation Medium Low fragmentation / High coordination Dementia - Alzheimer Rare diseases
  8. 8. A European Mobilization  Informal meeting on competitiveness for Ministers of Research, Versailles, 17th July 2008  Chaired by the French Minister of Higher Education and Research, Mrs Valérie Pécresse “to put the issue of neurodegenerative diseases in the top priorities of the agenda of the European Council.”“to launch a joint programme of research on these diseases, combining socio-economic and medico-biological issues.”
  9. 9. What is Joint Programming? • A new Member States-led initiative in Europe which aims to address “grand challenges” to EU society by coordinating national research programmes within the EU to increase the impact and effectiveness of research efforts.Source : Communication from the Commission to the European Parliament, theCouncil, the European Economic and social committee and the Committee of theRegions toward Joint Programming in Research : Working together to tacklecommon challenges more effectively - COM(2008) 468 final, Brussels
  10. 10. A major societal« Grand Challenge » Energy Climate Change Food & Health Neurodegeneration
  11. 11. Joint Programming - a definitionEuropean countries engaging• voluntarily and on a variable geometry basis to tackle a major societal question• in the definition, development and implementation of a common strategic research agenda• based on a common vision on how to address major societal challenges.
  12. 12. What are the goals?To tackle the challenge of Alzheimer’s and otherneurodegenerative diseases, the goals of the JPNDResearch Strategy are to• To develop new treatments and preventive strategies• To improve health and social care approaches• To raise awareness and de-stigmatise Neurodegenerative disorders• To alleviate the economic and social burden of these diseases
  13. 13. Organisation• Management Board • 25 countries represented • Mandated to act • Chair Prof Philippe Amouyel (France)• Executive Board • Vice-Chair Prof Adriana Maggi (Italy) • Enda Connolly (Ireland) • Edvard Beem (The Netherlands) • Mogens Horder (Denmark)• Scientific Advisory Board • 15 Members (5 in each domain) • Chosen for scientific excellence
  14. 14. JPND Research Strategy• JPND Research Strategy – what is it? • A holistic ‘roadmap’ for future EU-wide activity and investment • not a review of the field, not a list of calls for proposals• Delivery will take into account; • SAB recommendations – based upon outputs from 4 scientific/strategic workshops • National and European research portfolios • Broad consultation with stakeholder groups
  15. 15. Delivering JPND Research Strategy• 1. Mapping exercise of National and European programmes• 2. Strategic prioritisation • three thematic workshops (basic/clinical/healthcare) • Stakeholder discussions • fourth workshop to integrate outputs, incorporate stakeholder perspectives• 3. Consultation exercise (website publication)• 4. Delivery taking into account • Outputs from scientific workshops • Consultation • Discussion at MB (to incorporate funder, political & policy considerations)
  16. 16. JPND mapping €1.62bn investment – 357 programmes, 1887 smaller projects 238 bioresources captured Survey Section Entries Which represents:Organisational Details 75 Organisations from 21 countries €0.29 billion – 69 agencies from 21 countriesSmaller Investments 1887 + EC inc. ERC covering 1756 projects €1.33 billion - 41 funding agenciesMajor Programmes 357 (13 countries + EC inc. ERC)Research Networks 34 8 countries + Europe-widePopulation Cohorts 72 15 countries + Europe-wideCase Control Studies 22 9 countriesDisease Registries 21 9 countries + Europe-wideDNA, Tissue & Cell line Banks 87 15 countriesAnimal Model Repositories 12 8 countriesBio/Neuro Infrastructures 24 8 countries + Europe-wide
  17. 17. ND research spend by diseasearea (annualised) AD 31.4%ND general 41.7% MND 3% SMA 0.7% PD Prion HD 14.3% 5% SCA 3.7% 0.2%
  18. 18. Implementation and test-case• While waiting for JPND Research Strategy delivery, the Scientific Advisory Board recommended launching rapid actions• "Neurodegenerative Diseases - a call for European research projects for the optimisation of biomarkers and harmonisation of their use between clinical centres” • Launched by JPND on 13 May 2011 • 21 countries participating • Commitment for 16 M€ • Four projects retained on 7th Dec 2011
  19. 19. Other actions• The Centres of Excellence Network in Neurodegeneration Research initiative is considered as part of the JPND • initially DZNE-MRC-CIHR • now Germany, UK, Ireland, Canada, Belgium, Italy • - Topic : Biomarkers, Imaging, Animal models • - 4M€• The JPND supports the “JPIs TO CO-WORK” proposal submitted in February 2011 to “Refine and promote the adoption of European-level guidelines in the domain of the Framework conditions for JPI”• The JPND participates in the pilot European Innovation Partnership on Active and Healthy ageing
  20. 20. Towards Implementation Prof. Philippe Amouyel Chair, JPND Management Board
  21. 21. Implementation – 5 Steps• 1) Create List of priorities from JPND Research Startegy proposals• 2) Organise thematic working groups• 3) Create List of opportunities • suited for implementation• 4) Organise specific Task forces• 5) Support Implementation
  22. 22. Next Challenges• Implementation of the SRA• Developing national SRA• Funding commitment based on a 5 year period• Leverage effect• Based on existing mechanisms• Scale-up funding commitment For one specific call we obtained 16M€ commitment, for the whole SRA, we hope to gather larger amounts based on a country commitment accompanied by other participations (EU, Industry, stakeholders…)
  23. 23. Keep up to date• Visit the JPND website: • http://www.neurodegenerationresearch.eu • http://www.jpnd.eu• Search our Mapping Database• Sign up to the JPND News Feed• Follow us on Twitter: @JPNDEurope• E-mail us: secretariat@jpnd.eu

×